Specialty pharmaceutical company ANI Pharmaceuticals (NASDAQ: ANIP) will be reporting results this Friday before the bell. Here’s what to look for.
ANI Pharmaceuticals beat analysts’ revenue expectations by 10.4% last quarter, reporting revenues of $211.4 million, up 53.1% year on year. It was a stunning quarter for the company, with a beat of analysts’ EPS estimates and a solid beat of analysts’ revenue estimates.
Is ANI Pharmaceuticals a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting ANI Pharmaceuticals’s revenue to grow 44.3% year on year to $214.1 million, improving from the 12.5% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.77 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. ANI Pharmaceuticals has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 8.2% on average.
Looking at ANI Pharmaceuticals’s peers in the pharmaceuticals segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Amneal delivered year-on-year revenue growth of 11.7%, beating analysts’ expectations by 2.1%, and Eli Lilly reported revenues up 53.9%, topping estimates by 9.6%. Amneal traded up 3.7% following the results while Eli Lilly was also up 6%.
Read our full analysis of Amneal’s results here and Eli Lilly’s results here.
Investors in the pharmaceuticals segment have had steady hands going into earnings, with share prices up 1.6% on average over the last month. ANI Pharmaceuticals is up 3.1% during the same time and is heading into earnings with an average analyst price target of $107 (compared to the current share price of $94.49).
The biggest winners—Microsoft, Alphabet, Coca-Cola, Monster Beverage—were all riding powerful megatrends before Wall Street caught on. We’ve just identified an under-the-radar profitable growth stock positioned at the center of the AI boom. Get it FREE here before the crowd discovers it. GO HERE NOW.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
